206 related articles for article (PubMed ID: 7219643)
1. Suppression of secondary hyperparathyroidism by propranolol in renal failure patients.
Besarab A; Caro JF; Ihle BU; Burke JF; Glennon JA; Fischer JA
Nephron; 1981; 27(3):127-33. PubMed ID: 7219643
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. [Prevention and treatment of renal osteodystrophy: present and future].
Fernández E; Craver L
Nefrologia; 2006; 26 Suppl 3():19-27. PubMed ID: 17469423
[No Abstract] [Full Text] [Related]
4. Mineral and bone disorders in patients on dialysis: physiology and clinical consequences.
McCarley PB; Arjomand M
Nephrol Nurs J; 2008; 35(1):59-64. PubMed ID: 18372764
[TBL] [Abstract][Full Text] [Related]
5. A possible role for propranolol in the treatment of renal osteodystrophy.
Caro JF; Besarab A; Burke JF; Glennon JA
Lancet; 1978 Aug; 2(8087):451-4. PubMed ID: 79809
[TBL] [Abstract][Full Text] [Related]
6. [Long-term treatment of secondary hyperparathyroidism in the chronic hemodialysis patient with 1,25-(OH)2D3].
Giachino G; Giacchino F; Jeantet A; Del Piano A; Garetto A; Pellerey M; Piccoli G
Minerva Med; 1985 Mar; 76(9-10):407-14. PubMed ID: 2984605
[No Abstract] [Full Text] [Related]
7. Hyperparathyroidism in chronic renal failure and dialysis osteodystrophy.
O'Riordan JL; Page J; Kerr DN; Walls J; Moorhead J; Crockett RE; Franz H; Ritz E
Q J Med; 1970 Jul; 39(155):359-76. PubMed ID: 5478506
[No Abstract] [Full Text] [Related]
8. [PTH and bone metabolism in chronic dialysis patients].
Fukagawa M; Kazama J; Shigematsu T
Rinsho Byori; 2001 Mar; 49(3):236-8. PubMed ID: 11307321
[TBL] [Abstract][Full Text] [Related]
9. Effects of Lowering Dialysate Calcium Concentration on Mineral and Bone Disorders in Chronic Hemodialysis Patients: Conversion from 3.0 mEq/L to 2.75 mEq/L.
Yamada S; Ueki K; Tokumoto M; Suehiro T; Kimura H; Taniguchi M; Fujimi S; Kitazono T; Tsuruya K
Ther Apher Dial; 2016 Feb; 20(1):31-9. PubMed ID: 26482334
[TBL] [Abstract][Full Text] [Related]
10. [Clinical study on the disturbances in calcium and bone disease: renal osteodystrophy in patients with chronic renal failure].
Yoshidome E
Igaku Kenkyu; 1987 May; 57(2):83-104. PubMed ID: 3673482
[No Abstract] [Full Text] [Related]
11. Secondary hyperparathyroidism in chronic renal failure.
Wills MR; Savory J
Ann Clin Lab Sci; 1981; 11(3):252-61. PubMed ID: 6264838
[TBL] [Abstract][Full Text] [Related]
12. [Clinical evidence and treatment for optimum concentration of parathyroid hormone, calcium and phosphate in chronic renal failure].
Hoshino J; Ubara Y; Takaichi K
Clin Calcium; 2004 May; 14(5):731-7. PubMed ID: 15577034
[TBL] [Abstract][Full Text] [Related]
13. [Effect of strontium on bone metabolism in hemodialysis patients].
Gerstenfeld S; Hinojosa L; Serrano Arias M; Menéndez Rodríguez P; Fernández Martín JL; Marchante JM; García Alonso JI; Sanz-Medel A; Cannata Andía JB
Nefrologia; 2003; 23 Suppl 2():52-6. PubMed ID: 12778855
[TBL] [Abstract][Full Text] [Related]
14. Calcium and phosphate metabolism in chronic renal failure, with particular reference to the effect of 1 alpha-hydroxyvitamin D3.
Madsen S
Acta Med Scand Suppl; 1980; 638():3-120. PubMed ID: 6929650
[No Abstract] [Full Text] [Related]
15. The molecular basis of secondary hyperparathyroidism in chronic renal failure.
Rahamimov R; Silver J
Isr J Med Sci; 1994 Jan; 30(1):26-31. PubMed ID: 8138394
[TBL] [Abstract][Full Text] [Related]
16. Can a dietitian help prevent renal bone disease in the hemodialysis patient?
Harum P
Nephrol News Issues; 1990 Sep; 4(9):35, 37, 42. PubMed ID: 2402318
[No Abstract] [Full Text] [Related]
17. PTH and bone markers of renal osteodystrophy in predialysis chronic renal failure.
Coen G; Mazzaferro S; Ballanti P; Bonucci E
J Endocrinol Invest; 1992; 15(9 Suppl 6):129-33. PubMed ID: 1300330
[No Abstract] [Full Text] [Related]
18. [Parathyroid and bone. Management of parathyroid function and evaluation of bone metabolism in hemodialysis patients].
Goto S; Fukagawa M
Clin Calcium; 2007 Dec; 17(12):1830-4. PubMed ID: 18057657
[TBL] [Abstract][Full Text] [Related]
19. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
Brandi L; Daugaard H; Nielsen PK; Jensen LT; Egsmose C; Olgaard K
Nephron; 1996; 74(1):89-103. PubMed ID: 8883025
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor system components in hyperparathyroidism and renal osteodystrophy.
Jehle PM; Ostertag A; Schulten K; Schulz W; Jehle DR; Stracke S; Fiedler R; Deuber HJ; Keller F; Boehm BO; Baylink DJ; Mohan S
Kidney Int; 2000 Feb; 57(2):423-36. PubMed ID: 10652019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
